Theranostics 2018; 8(5):1389-1398. doi:10.7150/thno.20706 This issue

Research Paper

Longitudinal Multiplexed Measurement of Quantitative Proteomic Signatures in Mouse Lymphoma Models Using Magneto-Nanosensors

Jung-Rok Lee1, Iris Appelmann2,3, Cornelius Miething2,4, Tyler O. Shultz5, Daniel Ruderman6, Dokyoon Kim5, Parag Mallick7, Scott W. Lowe2, Shan X. Wang5,7,8✉

1. Division of Mechanical and Biomedical Engineering, Ewha Womans University, Seoul, South Korea
2. Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA
3. Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen, Germany
4. Department of Internal Medicine, Medical Center - University of Freiburg, Freiburg, Germany
5. Department of Materials Science and Engineering, Stanford University, Stanford, California, USA
6. Ellison Institute of Transformative Medicine of USC, USC Keck School of Medicine, Los Angeles, California, USA
7. Department of Medicine, Department of Radiology, Stanford University, Stanford, California, USA
8. Department of Electrical Engineering, Stanford University, Stanford, California, USA

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license ( See for full terms and conditions.
Lee JR, Appelmann I, Miething C, Shultz TO, Ruderman D, Kim D, Mallick P, Lowe SW, Wang SX. Longitudinal Multiplexed Measurement of Quantitative Proteomic Signatures in Mouse Lymphoma Models Using Magneto-Nanosensors. Theranostics 2018; 8(5):1389-1398. doi:10.7150/thno.20706. Available from

File import instruction


Graphic abstract

Cancer proteomics is the manifestation of relevant biological processes in cancer development. Thus, it reflects the activities of tumor cells, host-tumor interactions, and systemic responses to cancer therapy. To understand the causal effects of tumorigenesis or therapeutic intervention, longitudinal studies are greatly needed. However, most of the conventional mouse experiments are unlikely to accommodate frequent collection of serum samples with a large enough volume for multiple protein assays towards single-object analysis. Here, we present a technique based on magneto-nanosensors to longitudinally monitor the protein profiles in individual mice of lymphoma models using a small volume of a sample for multiplex assays.

Methods: Drug-sensitive and -resistant cancer cell lines were used to develop the mouse models that render different outcomes upon the drug treatment. Two groups of mice were inoculated with each cell line, and treated with either cyclophosphamide or vehicle solution. Serum samples taken longitudinally from each mouse in the groups were measured with 6-plex magneto-nanosensor cytokine assays. To find the origin of IL-6, experiments were performed using IL-6 knock-out mice.

Results: The differences in serum IL-6 and GCSF levels between the drug-treated and untreated groups were revealed by the magneto-nanosensor measurement on individual mice. Using the multiplex assays and mouse models, we found that IL-6 is secreted by the host in the presence of tumor cells upon the drug treatment.

Conclusion: The multiplex magneto-nanosensor assays enable longitudinal proteomic studies on mouse tumor models to understand tumor development and therapy mechanisms more precisely within a single biological object.

Keywords: Proteomic signature, magneto-nanosensors, longitudinal study, therapeutic intervention, mouse lymphoma, IL-6